TITLE:
Enhanced Analysis and Simplification of Scientific Findings with Emphasis on Katabasis and Anabasis on Safe and Effective Skin Cancer Treatment Using Curaderm
AUTHORS:
Kai Elliot Cham, Tania Robyn Chase, Bill Elliot Cham
KEYWORDS:
Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma, Curaderm, BEC, Mohs, Anabasis, Katabasis, Glycoalkaloids, Scarring, Superior Cosmetic Outcomes, Scarless, NMSC
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.16 No.4,
April
27,
2025
ABSTRACT: Skin cancer accounts for more cases annually than all other cancers combined. Traditional skin cancer treatments often fail to distinguish between cancerous and healthy skin cells, resulting in less effective outcomes and poor cosmetic results. In contrast, Curaderm cream, which contains antineoplastic BEC glycoalkaloids, selectively targets skin cancer cells while sparing healthy ones. This leads to effective healing with excellent cosmetic results. Here, we show that by using data from a Phase III clinical trial, the healing process works through two mechanisms: 1) Katabasis—eliminating cancer cells by apoptosis. 2) Anabasis—replacing them with healthy cells. Both processes occur at the same time, but their rates change during Curaderm therapy. These mechanisms explain the clinical observations that Curaderm-treated lesions first undergo transiently increased lesion sizes of up to 50%, followed by decreasing sizes until histological complete healing is achieved. At the end of treatment, the surface of the lesions becomes level with the surrounding healthy skin, is scarless, and is indistinguishable from untreated skin. These mechanisms ensure the complete removal and healing of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions without leaving scars.